116 filings
Page 4 of 6
8-K
icjwlwtq 068
28 Apr 20
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
4:50pm
8-K
c3i7o8d
31 Mar 20
Other Events
4:08pm
8-K
heafjkflw8g4f
26 Feb 20
CRISPR Therapeutics Proposes Changes to the Board of Directors
4:10pm
8-K
i16el k0pwvookn5zb16
12 Feb 20
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm
8-K
03tz7c 9eyzef0j4s7c
29 Jan 20
Departure of Directors or Certain Officers
4:16pm
8-K
pxyp0
27 Dec 19
Termination of a Material Definitive Agreement
4:06pm
8-K
xta6da
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
754dt11mnke14au0ye
22 Nov 19
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:02pm
8-K
j55ukw dt
19 Nov 19
Regulation FD Disclosure
8:21am
8-K
3fallrp4bla8azh
28 Oct 19
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
7:05am
8-K
q3ko91u e3hvla3
30 Aug 19
Entry into a Material Definitive Agreement
4:10pm
8-K
y56y u9mmqln5kuxvs4
29 Jul 19
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
4:05pm
8-K
j0ngoj5zu5r c4
26 Jun 19
Other Events
8:45am
8-K
iz206qd9a27o
13 Jun 19
Departure of Directors or Certain Officers
4:44pm
8-K
4zkrblo bsh73l
6 Jun 19
Entry into a Material Definitive Agreement
5:20pm
8-K
9h11ka1qzo0ji5it
29 Apr 19
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
4:05pm
8-K
74lfg
25 Feb 19
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
8:16am
8-K
hqnvn3ehleecm1lq
25 Feb 19
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
8:15am
8-K
zeony
9 Nov 18
Other Events
12:00am
8-K
ie05072jte6417
7 Nov 18
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
5:22pm